title: Time-dependent nephrotoxicity associated with daily administration of cisplatin in mice.
abstract: The chronopharmacokinetics and chronopharmacodynamics of cisplatin were studied in a mouse model to reveal the mechanisms of dosing time-dependent nephrotoxicity induced by daily administration. Chronotoxicity was tested by daily intraperitoneal injections of cisplatin (6mg kg(-1)) for 5 days at four time points (04:00, 10:00, 16:00 and 22:00h) in BALB/c mice (n = 6 in each group). After following the changes in body weight, serum concentrations of blood urea nitrogen (BUN) and creatinine obtained on day 6 were compared. The results showed diurnal variations in cisplatin toxicity, with the 04:00 and 16:00h time points the best and the worst, respectively. We then measured platinum concentrations in blood, liver and kidney and compared the results of the 04:00 and 16:00 h groups (n = 4 in each group). Kidney sensitivity to cisplatin alone, lipopolysaccharide (LPS) alone, cisplatin with LPS and saline (control) were also measured using a tissue culture system (a measurement system of interleukin-6 (IL-6) production) between the 04:00 and the 16:00 h groups (n = 4 in each group). These results showed no significant difference in platinum accumulation between the two groups. IL-6 production was higher in the 16:00 h group than in the 04:00 h group after saline injection alone (P < 0.05). Cisplatin treatment alone did not increase IL-6 production. However, IL-6 levels were markedly augmented by cisplatin with LPS. In conclusion, chrononephrotoxicity induced by daily cisplatin administration does not only depend on cisplatin accumulation, but might also depend on kidney sensitivity to diurnal variations in inflammatory reaction without direct cisplatin toxicity.
authors.affiliation: Department of Clinical Pharmacology, University of Occupational and Environmental Health, Kitakyushu, Japan.
authors.forename: H
authors.initials: H
authors.lastname: To
authors.forename: A
authors.initials: A
authors.lastname: Kikuchi
authors.forename: S
authors.initials: S
authors.lastname: Tsuruoka
authors.forename: K
authors.initials: K
authors.lastname: Sugimoto
authors.forename: A
authors.initials: A
authors.lastname: Fujimura
authors.forename: S
authors.initials: S
authors.lastname: Higuchi
authors.forename: F
authors.initials: F
authors.lastname: Kayama
authors.forename: K
authors.initials: K
authors.lastname: Hara
authors.forename: K
authors.initials: K
authors.lastname: Matsuno
authors.forename: E
authors.initials: E
authors.lastname: Kobayashi
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D001806:Blood Urea Nitrogen; D001835:Body Weight / Q000187:drug effects; D002940:Circadian Rhythm; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood; D003404:Creatinine / Q000097:blood; D004334:Drug Administration Schedule; D007274:Injections, Intraperitoneal; D015850:Interleukin-6 / Q000378:metabolism; D007668:Kidney / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D007674:Kidney Diseases / Q000139:chemically induced*; D008070:Lipopolysaccharides / Q000494:pharmacology; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D013997:Time Factors; D014018:Tissue Distribution
chemical_list: D000970:Antineoplastic Agents; D015850:Interleukin-6; D008070:Lipopolysaccharides; D003404:Creatinine; D002945:Cisplatin